A detailed history of Manufacturers Life Insurance Company, The transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 61,221 shares of APLS stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,221
Previous 73,135 16.29%
Holding current value
$2 Million
Previous $2.81 Million 37.08%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$28.84 - $41.15 $343,599 - $490,261
-11,914 Reduced 16.29%
61,221 $1.77 Million
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $1.91 Million - $3 Million
-50,195 Reduced 40.7%
73,135 $2.81 Million
Q1 2024

May 14, 2024

BUY
$55.39 - $72.47 $959,797 - $1.26 Million
17,328 Added 16.35%
123,330 $7.25 Million
Q4 2023

Feb 13, 2024

BUY
$37.14 - $64.82 $1.92 Million - $3.35 Million
51,737 Added 95.34%
106,002 $6.35 Million
Q3 2023

Nov 15, 2023

SELL
$23.65 - $89.22 $2.73 Million - $10.3 Million
-115,408 Reduced 68.02%
54,265 $2.06 Million
Q2 2023

Aug 11, 2023

BUY
$76.68 - $93.31 $6.66 Million - $8.1 Million
86,843 Added 104.84%
169,673 $15.5 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $2.5 Million - $3.6 Million
53,766 Added 64.91%
136,596 $9.01 Million
Q4 2022

Aug 11, 2023

SELL
$43.24 - $61.04 $443,382 - $625,904
-10,254 Reduced 11.02%
82,830 $4.28 Million
Q4 2022

Feb 13, 2023

SELL
$43.24 - $61.04 $443,382 - $625,904
-10,254 Reduced 11.02%
82,830 $4.28 Million
Q3 2022

Aug 11, 2023

SELL
$44.76 - $69.66 $169,729 - $264,150
-3,792 Reduced 3.91%
93,084 $6.36 Million
Q3 2022

Nov 03, 2022

SELL
$44.76 - $69.66 $169,729 - $264,150
-3,792 Reduced 3.91%
93,084 $6.19 Million
Q2 2022

Aug 11, 2023

SELL
$35.07 - $59.21 $120,044 - $202,675
-3,423 Reduced 3.41%
96,876 $4.38 Million
Q2 2022

Aug 15, 2022

SELL
$35.07 - $59.21 $120,044 - $202,675
-3,423 Reduced 3.41%
96,876 $4.38 Million
Q1 2022

Aug 11, 2023

SELL
$35.46 - $54.12 $1.29 Million - $1.96 Million
-36,297 Reduced 26.57%
100,299 $5.1 Million
Q1 2022

May 20, 2022

BUY
$35.46 - $54.12 $2.28 Million - $3.48 Million
64,350 Added 179.0%
100,299 $5 Million
Q4 2021

Feb 16, 2022

BUY
$30.74 - $49.16 $59,174 - $94,633
1,925 Added 5.66%
35,949 $1.72 Million
Q3 2021

Nov 12, 2021

SELL
$31.4 - $69.84 $85,816 - $190,872
-2,733 Reduced 7.44%
34,024 $1.12 Million
Q2 2021

Aug 12, 2021

BUY
$40.9 - $64.9 $103,926 - $164,910
2,541 Added 7.43%
36,757 $2.32 Million
Q1 2021

May 03, 2021

SELL
$40.8 - $57.39 $84,129 - $118,338
-2,062 Reduced 5.68%
34,216 $1.47 Million
Q4 2020

Feb 12, 2021

BUY
$30.79 - $57.2 $28,942 - $53,768
940 Added 2.66%
36,278 $2.08 Million
Q3 2020

Nov 09, 2020

SELL
$25.89 - $33.65 $16,440 - $21,367
-635 Reduced 1.77%
35,338 $1.07 Million
Q2 2020

Aug 10, 2020

BUY
$24.8 - $38.49 $5,728 - $8,891
231 Added 0.65%
35,973 $1.11 Million
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $110,880 - $274,447
6,191 Added 20.95%
35,742 $958,000
Q4 2019

Feb 14, 2020

SELL
$22.1 - $30.8 $24,884 - $34,680
-1,126 Reduced 3.67%
29,551 $905,000
Q3 2019

Nov 12, 2019

BUY
$24.09 - $32.18 $5,974 - $7,980
248 Added 0.82%
30,677 $749,000
Q2 2019

Aug 14, 2019

BUY
$18.0 - $25.34 $106,524 - $149,962
5,918 Added 24.14%
30,429 $771,000
Q1 2019

May 13, 2019

BUY
$12.81 - $19.82 $23,019 - $35,616
1,797 Added 7.91%
24,511 $478,000
Q4 2018

Feb 14, 2019

SELL
$11.47 - $18.71 $20,898 - $34,089
-1,822 Reduced 7.43%
22,714 $299,000
Q3 2018

Nov 14, 2018

SELL
$16.57 - $21.03 $49,345 - $62,627
-2,978 Reduced 10.82%
24,536 $436,000
Q2 2018

Aug 14, 2018

BUY
$19.63 - $30.0 $351,612 - $537,360
17,912 Added 186.54%
27,514 $606,000
Q1 2018

May 15, 2018

BUY
$14.01 - $26.02 $14,724 - $27,347
1,051 Added 12.29%
9,602 $213,000
Q4 2017

Feb 08, 2018

BUY
$12.71 - $21.7 $108,683 - $185,556
8,551
8,551 $186,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.59B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.